Utpal B. Pajvani

Utpal B. Pajvani

Auto-generated profile, based on publicly available information

Utpal B. Pajvani


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CZChangyu Zhu
Changyu Zhu
KKKyeongJin Kim
KyeongJin Kim
XWXiaobo Wang
Xiaobo Wang
Alberto BartoloméAlberto Bartolomé
Alberto Bartolomé
MSMarcela Salomao
Marcela Salomao
UPUtpal B. Pajvani
Utpal B. Pajvani
Fibrosis is the major determinant of morbidity and mortality in patients with nonalcoholic steatohepatitis (NASH) but has no approved pharmacotherapy in part because of incomplete understanding of its pathogenic mechanisms. Here, we report that hepatocyte Notch activity tracks with disease severity and treatment response in patients with NASH and is similarly increased in a mouse model of diet-induced NASH and liver fibrosis. Hepatocyte-specific Notch loss-of-function mouse models showed attenuated NASH-associated liver fibrosis, demonstrating causality to obesity-induced liver pathology. Conversely, forced activation of hepatocyte Notch induced fibrosis in both chow- and NASH diet–fed mice by increasing Sox9-dependent Osteopontin (Opn) expression and secretion from hepatocytes, which activate resident hepatic stellate cells. In a cross-sectional study, we found that OPN explains the positive correlation between liver Notch activity and fibrosis stage in patients. Further, we developed a Notch inhibitor [Nicastrin antisense oligonucleotide (Ncst ASO)] that reduced fibrosis in NASH diet–fed mice. In summary, these studies demonstrate the pathological role and therapeutic accessibility of the maladaptive hepatocyte Notch response in NASH-associated liver fibrosis.

5 April 2024 in Liver International
Verified
Journal Article
Open access
SPSalvatore Petta
Salvatore Petta
Giovanni TargherGiovanni Targher
Giovanni Targher
SRStefano Romeo
Stefano Romeo
UPUtpal B. Pajvani
Utpal B. Pajvani
MZMing-Hua Zheng
Ming-Hua Zheng
LVLuca Valenti
Luca Valenti
The rising prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) poses a significant global health challenge, affecting over 30% of adults worldwide. MASLD is linked to increased mortality rates and substantial healthcare costs, primarily driven by its progression to metabolic dysfunction‐associated steatohepatitis (MASH), which can lead to severe liver complications including cirrhosis and hepatocellular carcinoma. Despite its growing burden, effective pharmacotherapy for MASLD/MASH has been lacking until the recent conditional approval of resmetirom by the FDA. Resmetirom, a liver‐targeted thyroid hormone receptor‐β selective drug, has shown promise in clinical trials for treating non‐cirrhotic MASH with moderate to advanced fibrosis. It has demonstrated efficacy in reducing hepatic fat content, improving liver histology (both MASH resolution and fibrosis improvement), and ameliorating biomarkers of liver damage without significant effects on body weight or glucose metabolism. Notably, resmetirom also exhibits favourable effects on circulating lipids, potentially reducing cardiovascular risk in MASLD/MASH patients. The safety profile of resmetirom appears acceptable, with gastrointestinal adverse events being the most common, though generally mild or moderate. However, long‐term surveillance is warranted to monitor for potential risks related to thyroid, gonadal, or bone diseases. Clinical implementation of resmetirom faces challenges in patient selection and monitoring treatment response, and will heavily rely on non‐invasive tests for liver fibrosis assessment. Nonetheless, resmetirom represents a landmark breakthrough in MASLD/MASH treatment, paving the way for future therapeutic strategies aiming to mitigate the multifaceted risks associated with this complex metabolic liver disease.

7 July 2013 in Nature Medicine
Verified
Journal Article
Open access
PDF file
UPUtpal B Pajvani
Utpal B Pajvani
QLQiang Li
Qiang Li
TKThaned Kangsamaksin
Thaned Kangsamaksin
JKJan Kitajewski
Jan Kitajewski
HGHenry N Ginsberg
Henry N Ginsberg
DADomenico Accili
Domenico Accili
Hepatic insulin resistance, a hallmark of type 2 diabetes, results in elevated blood sugar concentrations and fatty liver disease. Domenico Accili and his colleagues now show that inhibition of Notch signaling in the liver dampens the pathways leading to both conditions, thus improving these aspects of diabetes. Increased hepatic lipid content is an early correlate of insulin resistance and can be caused by nutrient-induced activation of mammalian target of rapamycin (mTor). This activation of mTor increases basal Akt activity, leading to a self-perpetuating lipogenic cycle. We have previously shown that the developmental Notch pathway has metabolic functions in adult mouse liver. Acute or chronic inhibition of Notch dampens hepatic glucose production and increases Akt activity and may therefore be predicted to increase hepatic lipid content. Here we now show that constitutive liver-specific ablation of Notch signaling, or its acute inhibition with a decoy Notch1 receptor, prevents hepatosteatosis by blocking mTor complex 1 (mTorc1) activity. Conversely, Notch gain of function causes fatty liver through constitutive activation of mTorc1, an effect that is reversible by treatment with rapamycin. We demonstrate that Notch signaling increases mTorc1 complex stability, augmenting mTorc1 function and sterol regulatory element binding transcription factor 1c (Srebp1c)-mediated lipogenesis. These data identify Notch as a therapeutically actionable branch point of metabolic signaling at which Akt activation in the liver can be uncoupled from hepatosteatosis.

1 December 2017 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
Alberto BartoloméAlberto Bartolomé
Alberto Bartolomé
AAAna García Aguilar
Ana García Aguilar
SAShun-Ichiro Asahara
Shun-Ichiro Asahara
YKYoshiaki Kido
Yoshiaki Kido
Carlos GuillénCarlos Guillén
Carlos Guillén
MBManuel Benito
Manuel Benito
Mechanistic target of rapamycin complex 1 (MTORC1) is a critical negative regulator of general autophagy. We hypothesized that MTORC1 may specifically regulate autophagic clearance of damaged mitochondria. To test this, we used cells lacking tuberous sclerosis complex 2 (TSC2−/− cells), which show constitutive MTORC1 activation. TSC2−/− cells show MTORC1-dependent impaired autophagic flux after chemical uncoupling of mitochondria, increased mitochondrial-protein aging, and accumulation of p62/SQSTM1-positive mitochondria. Mitochondrial autophagy (mitophagy) was also deficient in cells lacking TSC2, associated with altered expression of PTEN-induced putative kinase 1 (PINK1) and PARK2 translocation to uncoupled mitochondria, all of which were recovered by MTORC1 inhibition or expression of constitutively active forkhead box protein O1 (FoxO1). These data prove the necessity of intact MTORC1 signaling to regulate two synergistic processes required for clearance of damaged mitochondria: (i) general autophagy initiation and (ii) PINK1/PARK2-mediated selective targeting of uncoupled mitochondria to the autophagic machinery.

23 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JYJunjie Yu
Junjie Yu
CZChangyu Zhu
Changyu Zhu
XWXiaobo Wang
Xiaobo Wang
KKKyeongJin Kim
KyeongJin Kim
Alberto BartoloméAlberto Bartolomé
Alberto Bartolomé
UPUtpal B. Pajvani
Utpal B. Pajvani
Aberrant hepatocyte Notch activity is critical to the development of nonalcoholic steatohepatitis (NASH)–induced liver fibrosis, but mechanisms underlying Notch reactivation in developed liver are unclear. Here, we identified that increased expression of the Notch ligand Jagged1 (JAG1) tracked with Notch activation and nonalcoholic fatty liver disease (NAFLD) activity score (NAS) in human liver biopsy specimens and mouse NASH models. The increase in Jag1 was mediated by hepatocyte Toll-like receptor 4 (TLR4)–nuclear factor κB (NF-κB) signaling in pericentral hepatocytes. Hepatocyte-specific Jag1 overexpression exacerbated fibrosis in mice fed a high-fat diet or a NASH-provoking diet rich in palmitate, cholesterol, and sucrose and reversed the protection afforded by hepatocyte-specific TLR4 deletion, whereas hepatocyte-specific Jag1 knockout mice were protected from NASH-induced liver fibrosis. To test therapeutic potential of this biology, we designed a Jag1-directed antisense oligonucleotide (ASO) and a hepatocyte-specific N-acetylgalactosamine (GalNAc)–modified siRNA, both of which reduced NASH diet–induced liver fibrosis in mice. Overall, these data demonstrate that increased hepatocyte Jagged1 is the proximal hit for Notch-induced liver fibrosis in mice and suggest translational potential of Jagged1 inhibitors in patients with NASH.

13 October 2020 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
CZChangyu Zhu
Changyu Zhu
ITIra Tabas
Ira Tabas
RSRobert F. Schwabe
Robert F. Schwabe
UPUtpal B. Pajvani
Utpal B. Pajvani